CY1120761T1 - Ενεσιμη συνθεση αιωρηματος που αποτελειται απο βουπρενορφινη - Google Patents
Ενεσιμη συνθεση αιωρηματος που αποτελειται απο βουπρενορφινηInfo
- Publication number
- CY1120761T1 CY1120761T1 CY181100098T CY181100098T CY1120761T1 CY 1120761 T1 CY1120761 T1 CY 1120761T1 CY 181100098 T CY181100098 T CY 181100098T CY 181100098 T CY181100098 T CY 181100098T CY 1120761 T1 CY1120761 T1 CY 1120761T1
- Authority
- CY
- Cyprus
- Prior art keywords
- buprenorphine
- buprenorphin
- injective
- sustained release
- release system
- Prior art date
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000725 suspension Substances 0.000 title 1
- 229960001736 buprenorphine Drugs 0.000 abstract 4
- 238000013268 sustained release Methods 0.000 abstract 3
- 239000012730 sustained-release form Substances 0.000 abstract 3
- 239000007943 implant Substances 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 239000012530 fluid Substances 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 206010028320 muscle necrosis Diseases 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1009549.5A GB2481018B (en) | 2010-06-08 | 2010-06-08 | Injectable flowable composition comprising buprenorphine |
| PCT/GB2011/051057 WO2011154724A2 (en) | 2010-06-08 | 2011-06-06 | Compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120761T1 true CY1120761T1 (el) | 2019-12-11 |
Family
ID=42471306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY181100098T CY1120761T1 (el) | 2010-06-08 | 2018-01-24 | Ενεσιμη συνθεση αιωρηματος που αποτελειται απο βουπρενορφινη |
Country Status (32)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8470359B2 (en) | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| GB2513267B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| WO2013126552A1 (en) * | 2012-02-21 | 2013-08-29 | Auburn University | Buprenorphine nanoparticle composition and methods thereof |
| JP6279547B2 (ja) | 2012-04-17 | 2018-02-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法 |
| IL296882A (en) * | 2012-07-26 | 2022-12-01 | Camurus Ab | Opioid formulations |
| KR102098980B1 (ko) | 2012-07-26 | 2020-04-08 | 카무러스 에이비 | 오피오이드 제형 |
| EP2931253A1 (en) * | 2012-12-13 | 2015-10-21 | Heron Therapeutics, Inc. | Pharmaceutical composition comprising antiemetic compounds and polyorthoester |
| US9636308B2 (en) | 2013-03-15 | 2017-05-02 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| US9393211B2 (en) * | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| WO2014143635A1 (en) * | 2013-03-15 | 2014-09-18 | Heron Therapeutics, Inc. | Compositions of a polyorthoester and an aprotic solvent |
| GB201404139D0 (en) * | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| EP3509601A1 (en) | 2014-04-21 | 2019-07-17 | Heron Therapeutics, Inc. | A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam |
| HUE052224T2 (hu) * | 2014-04-21 | 2021-04-28 | Heron Therapeutics Inc | Poliortoészterbõl és szerves sav segédanyagból álló készítmények |
| US9801945B2 (en) | 2014-04-21 | 2017-10-31 | Heron Therapeutics, Inc. | Long-acting polymeric delivery systems |
| CA2946281C (en) | 2014-04-21 | 2022-12-13 | Heron Therapeutics, Inc. | Long-acting polymeric delivery systems |
| CN106470999B (zh) | 2014-04-28 | 2018-11-13 | 奥佛麦德公司 | 叔丁啡二聚体及其在治疗肠胃失调中的应用 |
| GB201419091D0 (en) * | 2014-10-27 | 2014-12-10 | Camurus Ab | Formulations |
| WO2016071767A1 (en) * | 2014-11-07 | 2016-05-12 | Indivior Uk Limited | Buprenorphine dosing regimens |
| US10786515B2 (en) | 2015-08-03 | 2020-09-29 | Tolmar International Limited | Liquid polymer delivery system for extended administration of drugs |
| FI3377041T3 (fi) | 2015-11-16 | 2023-11-30 | Medincell S A | Menetelmä farmaseuttisesti aktiivisten pääainesosien morselloimiseksi ja/tai kohdentamiseksi synoviaalikudokseen |
| CA3033046C (en) * | 2016-09-13 | 2021-09-07 | Alar Pharmaceuticals Inc. | Sustained-release buprenorphine formulations |
| EP3638240A2 (en) | 2017-06-16 | 2020-04-22 | Indivior UK Limited | Methods to treat opioid use disorder |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| AU2019209416A1 (en) | 2018-01-22 | 2020-07-30 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition for sustained release delivery of buprenorphine |
| AR117426A1 (es) * | 2018-05-11 | 2021-08-04 | Alar Pharmaceuticals Inc | Formulaciones inyectables de acción prolongada y formas cristalinas de derivados de buprenorfina |
| EP3863712A4 (en) | 2018-10-11 | 2022-07-20 | Indivior UK Limited | Buprenorphine to treat respiratory depression |
| US12403291B2 (en) | 2019-08-30 | 2025-09-02 | Intersect Ent, Inc. | Submucosal bioresorbable drug eluting platform |
| CN118831057A (zh) * | 2023-04-25 | 2024-10-25 | 深圳善康医药科技股份有限公司 | 丁丙诺啡植入剂及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| DE69534780T2 (de) | 1994-04-08 | 2006-10-05 | Qlt Usa Inc., Fort Collins | Flüssige Zusammensetzungen zur Arzneistoffabgabe |
| US20030211157A1 (en) * | 1996-05-06 | 2003-11-13 | Simon David Lew | Semi-sol delivery blend for water soluble molecules |
| US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| SI2561860T1 (en) * | 2002-05-31 | 2018-05-31 | Titan Pharmaceuticals, Inc. | An implantable polymeric device for prolonged release of buprenorphine |
| US7368126B2 (en) * | 2002-11-06 | 2008-05-06 | Guohua Chen | Controlled release depot formulations |
| JP2007525429A (ja) * | 2003-03-11 | 2007-09-06 | キューエルティー ユーエスエー，インコーポレイテッド． | 細胞スケジュール依存性抗癌剤のための処方 |
| JP2008520547A (ja) * | 2004-10-04 | 2008-06-19 | キューエルティー ユーエスエー，インコーポレイテッド． | 眼部送達のためのポリマー送達処方 |
| AU2005304435B8 (en) * | 2004-11-10 | 2011-06-23 | Tolmar Therapeutics, Inc. | A stabilized polymeric delivery system |
| HUE025842T2 (en) | 2007-02-15 | 2016-04-28 | Tolmar Therapeutics Inc | Poly (lactide / glycolide) with reduced fracture properties and methods for producing polymers |
| US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| GB2513267B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
-
2010
- 2010-06-08 GB GB1413064.5A patent/GB2513267B/en active Active
- 2010-06-08 GB GB1009549.5A patent/GB2481018B/en active Active
-
2011
- 2011-06-06 NZ NZ604026A patent/NZ604026A/en unknown
- 2011-06-06 WO PCT/GB2011/051057 patent/WO2011154724A2/en not_active Ceased
- 2011-06-06 JP JP2013513755A patent/JP5986072B2/ja not_active Expired - Fee Related
- 2011-06-06 US US13/703,013 patent/US8921387B2/en active Active
- 2011-06-06 EP EP17205986.7A patent/EP3360538B1/en active Active
- 2011-06-06 PT PT117280370T patent/PT2579874T/pt unknown
- 2011-06-06 NO NO11728037A patent/NO2579874T3/no unknown
- 2011-06-06 BR BR112012031290A patent/BR112012031290A2/pt not_active Application Discontinuation
- 2011-06-06 FI FIEP17205986.7T patent/FI3360538T3/fi active
- 2011-06-06 KR KR1020127032282A patent/KR101865689B1/ko not_active Expired - Fee Related
- 2011-06-06 SI SI201131401T patent/SI2579874T1/en unknown
- 2011-06-06 SG SG2012089652A patent/SG186200A1/en unknown
- 2011-06-06 MY MYPI2012005274A patent/MY171625A/en unknown
- 2011-06-06 MX MX2012014335A patent/MX339209B/es active IP Right Grant
- 2011-06-06 EP EP23150636.1A patent/EP4218720A1/en active Pending
- 2011-06-06 EP EP11728037.0A patent/EP2579874B1/en active Active
- 2011-06-06 HR HRP20180118TT patent/HRP20180118T1/hr unknown
- 2011-06-06 PL PL11728037T patent/PL2579874T3/pl unknown
- 2011-06-06 LT LTEP11728037.0T patent/LT2579874T/lt unknown
- 2011-06-06 RU RU2012157244A patent/RU2607498C2/ru not_active IP Right Cessation
- 2011-06-06 HU HUE11728037A patent/HUE038275T2/hu unknown
- 2011-06-06 CA CA2801676A patent/CA2801676C/en active Active
- 2011-06-06 ES ES11728037.0T patent/ES2656938T3/es active Active
- 2011-06-06 RS RS20180068A patent/RS56820B1/sr unknown
- 2011-06-06 DK DK11728037.0T patent/DK2579874T3/da active
- 2011-06-06 AU AU2011263478A patent/AU2011263478B2/en active Active
- 2011-06-06 SM SM20180038T patent/SMT201800038T1/it unknown
- 2011-06-06 CN CN201180039223.3A patent/CN103079544B/zh not_active Expired - Fee Related
- 2011-06-06 ES ES17205986T patent/ES2939612T3/es active Active
- 2011-06-06 DK DK17205986.7T patent/DK3360538T3/da active
-
2012
- 2012-12-06 IL IL223488A patent/IL223488A/en active IP Right Grant
- 2012-12-06 ZA ZA2012/09233A patent/ZA201209233B/en unknown
- 2012-12-07 CL CL2012003462A patent/CL2012003462A1/es unknown
-
2013
- 2013-01-04 CO CO13001795A patent/CO6670529A2/es unknown
-
2016
- 2016-06-01 JP JP2016110259A patent/JP6251774B2/ja active Active
-
2017
- 2017-09-11 IL IL254417A patent/IL254417A0/en unknown
-
2018
- 2018-01-24 CY CY181100098T patent/CY1120761T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120761T1 (el) | Ενεσιμη συνθεση αιωρηματος που αποτελειται απο βουπρενορφινη | |
| CY1122984T1 (el) | Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους | |
| CY1118232T1 (el) | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων | |
| CY1122695T1 (el) | Αλας toy omecamtiv mecarbil και διαδικασια για την παρασκευη αλατος | |
| CY1123577T1 (el) | Ενωσεις 7-φαινυλοαιθυλαμινο-4η-πυριμιδο[4,5-d][1,3]οξαζιν-2-ονης ως αναστολεις μεταλλαγμενου idh1 και idh2 | |
| CY1123626T1 (el) | Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης | |
| CY1121858T1 (el) | Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτες και μεθοδοι χρησης αυτων | |
| CY1118307T1 (el) | Συνθεσεις που περιλαμβανουν βουπρενορφινη (buprenorphine) | |
| UA109417C2 (uk) | ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ | |
| CL2013001381A1 (es) | Compuestos derivados de hidroxi-amida pirimidina, inhibidores de la proteina deacetilasa hdac6; composicion farmaceutica; combinación farmaceutica; metodos de uso para el tratamiento de una enfermedad proliferativa o cancer; un kit | |
| PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| BR112016015236A8 (pt) | composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença. | |
| CY1118128T1 (el) | Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2 | |
| CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
| CY1113422T1 (el) | Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842 | |
| TN2012000392A1 (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| CY1125157T1 (el) | Ενεσιμες συνθεσεις που εμπεριεχουν λετροζολη ή αναστροζολη | |
| CY1118541T1 (el) | D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης | |
| CY1117489T1 (el) | Συνθεση δινατριου αλατος της ν4-(2,2-διμεθυλ-4-[(διυδρογονο φωσφονοξυ) μεθυλ]-3-οξο-5-πυριδο [1,4] οξαζιν-6-υλ)-5-φθορο-ν2-(3,4,5-τριμεθοξυφαινυλ)-2,4-πυριμιδινοδιαμινης | |
| EA201170483A1 (ru) | Твердая фармацевтическая композиция | |
| CY1119547T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι χρησιμες για κινητοποιηση χοληστερολης | |
| AR085173A1 (es) | Terapia de combinacion para el tratamiento de enfermedades oncologicas y fibroticas | |
| CY1118036T1 (el) | Βελτιστοποιημενη συνθεση καθαρων μη-πολυμορφικων, κρυσταλλικων χολικων οξεων με καθορισμενο μεγεθος σωματιδιων | |
| CY1122170T1 (el) | Ορβεπιταντη για τη θεραπευτικη αγωγη χρονιου βηχα | |
| BRPI0903914A2 (pt) | Uso de um composto, método para analisar a eficácia de uma composição de liberação prolongada, e, composição farmacêutica. |